05.21.13
Integra on a New Product Roll
Integra Lifesciences Holdings Corp. introduced several new products during the annual meeting of the American Association of Neurological Surgeons, held this year in New Orleans, La., from April 27 to May 1.
On April 30, the company announced the full market release of its Hollywood VI intervertebral body fusion device system. The Hollywood VI IBD is used primarily in transforaminal lumbar interbody fusion, a surgical procedure designed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
The device incorporates a variable insertion feature, designed to enable surgeons to choose the appropriate delivery angle for the implant and gives more flexibility in managing varying patient anatomy. It includes a new, longer, 30-mm implant that increases the bone graft volume by 33 percent compared with the current 27-mm implant, and provides a larger platform to help promote spinal fusion.
Thomas N. Scioscia, M.D., an orthopedic surgeon based in Richmond, Va., said the device is “simple to insert, due to the variable angle insertion mechanism, while maximizing fusion rates by aggressively increasing graft space within the cage, compared to its competitors.”
Integra also introduced the Integra compact cranial closure system, which provides titanium implants for non-loadbearing (non-facial) operative cranial neurosurgical procedures. Included with the system is a pre-sterilized, disposable, battery powered screwdriver that is used for rapid fixation of the implant’s plates and screws. Both the closure system and the drill have received 510(k) clearance from the United States Food and Drug Administration (FDA).
The compact cranial closure system includes a small tray design, which reportedly enhances efficiency in both the operating room and the hospital central sterilization department, and low-profile plates made of titanium alloys that are thin to enhance patient aesthetics, according to the company. The new pre-sterilized, disposable, battery powered screwdriver is designed to offer neurosurgeons more convenience in a single-use, portable device.
“Our new cranial closure system helps round out our neurosurgical product offerings,” said Pete Ligotti, Integra’s vice president of marketing, neurosurgery. “Cranial closure occurs immediately following repair of the dural lining surrounding the brain. We offer an extensive line of our Duragen products for dural repair, and now, with our new cranial closure system, we provide neurosurgeons with the full line of products that they need for a cranial closure procedure.”
The third offering from Integra is the next generation of its Camino platform, a monitoring system for continuous intracranial pressure monitoring and cerebral spinal fluid drainage. The Camino platform technologies are aimed at conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage and stroke.
The new Camino platform includes the Integra Camino ICP and temperature monitor and Integra Camino Flex ventricular catheter, which uses strain gauge technology. The monitor and catheter have been cleared by the FDA under its 510(k) process.
Ligotti said that the company is releasing the Camino monitor alongside a tunneled advanced monitoring catheter (the Camino Flex) to make it easier for surgeons to take advantage of Integra’s latest technology.
Headquartered in Plainsboro, N.J., Integra makes surgical technology for orthopedic extremity, neurosurgery, spine, reconstructive and general surgery.
Integra Lifesciences Holdings Corp. introduced several new products during the annual meeting of the American Association of Neurological Surgeons, held this year in New Orleans, La., from April 27 to May 1.
On April 30, the company announced the full market release of its Hollywood VI intervertebral body fusion device system. The Hollywood VI IBD is used primarily in transforaminal lumbar interbody fusion, a surgical procedure designed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
The device incorporates a variable insertion feature, designed to enable surgeons to choose the appropriate delivery angle for the implant and gives more flexibility in managing varying patient anatomy. It includes a new, longer, 30-mm implant that increases the bone graft volume by 33 percent compared with the current 27-mm implant, and provides a larger platform to help promote spinal fusion.
Thomas N. Scioscia, M.D., an orthopedic surgeon based in Richmond, Va., said the device is “simple to insert, due to the variable angle insertion mechanism, while maximizing fusion rates by aggressively increasing graft space within the cage, compared to its competitors.”
Integra also introduced the Integra compact cranial closure system, which provides titanium implants for non-loadbearing (non-facial) operative cranial neurosurgical procedures. Included with the system is a pre-sterilized, disposable, battery powered screwdriver that is used for rapid fixation of the implant’s plates and screws. Both the closure system and the drill have received 510(k) clearance from the United States Food and Drug Administration (FDA).
The compact cranial closure system includes a small tray design, which reportedly enhances efficiency in both the operating room and the hospital central sterilization department, and low-profile plates made of titanium alloys that are thin to enhance patient aesthetics, according to the company. The new pre-sterilized, disposable, battery powered screwdriver is designed to offer neurosurgeons more convenience in a single-use, portable device.
“Our new cranial closure system helps round out our neurosurgical product offerings,” said Pete Ligotti, Integra’s vice president of marketing, neurosurgery. “Cranial closure occurs immediately following repair of the dural lining surrounding the brain. We offer an extensive line of our Duragen products for dural repair, and now, with our new cranial closure system, we provide neurosurgeons with the full line of products that they need for a cranial closure procedure.”
The third offering from Integra is the next generation of its Camino platform, a monitoring system for continuous intracranial pressure monitoring and cerebral spinal fluid drainage. The Camino platform technologies are aimed at conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage and stroke.
The new Camino platform includes the Integra Camino ICP and temperature monitor and Integra Camino Flex ventricular catheter, which uses strain gauge technology. The monitor and catheter have been cleared by the FDA under its 510(k) process.
Ligotti said that the company is releasing the Camino monitor alongside a tunneled advanced monitoring catheter (the Camino Flex) to make it easier for surgeons to take advantage of Integra’s latest technology.
Headquartered in Plainsboro, N.J., Integra makes surgical technology for orthopedic extremity, neurosurgery, spine, reconstructive and general surgery.